-
[Updated] Longevity Medicine Beyond the Messenger
Originally published November 4, 2025. Updated February 2026. As clinicians and scientists, we often engage with ideas, frameworks, and data that are communicated through books, podcasts, or public figures. It is critical to be clear about where our professional endorsement begins and ends. This article reflects a review of the scientific concepts presented in Outlive: The Science and Art of Longevity. It does not represent support for, or alignment with, the personal actions or conduct of Dr. Peter Attia. Recent reporting has raised serious ethical concerns, and I want to state clearly that I do not condone or excuse any…
-
Dietary Guidelines vs. Diabetes Care: What Works, What Doesn’t
If you work in the nutrition, wellness, or public health space or honestly if you were just on the internet this week, you probably noticed the stir around the release of the new Dietary Guidelines for Americans. The 2025–2030 update has arrived with no shortage of commentary, critique, endorsements, and of course, funny and creative memes. Love them or hate them, these guidelines are clearly fueling plenty of online chatter. But what does all of this actually mean for people living with diabetes? Are these new guidelines helpful or harmful? And how do they stack up against the nutrition guidance outlined…
-
The State of Wellness: Glucose Tracking Is Having a Moment
If you’re not already using continuous glucose monitoring (CGM) in your practice, it’s time to start. Catch up or risk getting left behind, because glucose tracking for metabolic health is having a moment. From diabetes prevention to metabolic optimization and athletic performance, CGM is everywhere. And it’s easier than ever to get started. With just a few clicks, direct-to-consumer CGMs like Abbott’s Lingo and Dexcom’s Stelo can be delivered straight to your doorstep, sometimes in less than 24 hours. I know, because I’ve tried them myself! Earlier this year, Abbott released a white paper on the state of wellness, exploring…
-
What’s the Deal with GLP-1 Microdosing?
Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask. Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation. Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who…
-
Does CGM Tell the Whole Story? A Second Look at Lingo for Metabolic Monitoring
I recently revisited Lingo, Abbott’s direct-to-consumer continuous glucose monitoring (CGM) system, after a new wave of clients began seeking guidance on how to use it to support metabolic health, including diabetes prevention, insulin resistance, and weight loss. Last fall, I tested and reviewed the device with a focus on its hardware, technical features, usability, and accuracy. This time, however, I’m evaluating Lingo from a different angle: its potential role in health coaching and behavior change. What can continuous glucose monitoring really tell us about metabolic health—or overall well-being? Does it provide the full picture? More importantly, how does it actually…
-
Double Diabetes: Supporting Patients Through the Diagnostic Overlap
If you’ve never heard the term “double diabetes” before, don’t be alarmed. It’s not an official diagnosis, and you likely won’t find it in a medical textbook. However, it’s a term that’s gaining traction to describe a growing population of adults whose diabetes doesn’t fit neatly into the diagnostic criteria for either type 1 or type 2. Sometimes referred to as “hybrid diabetes,” “type 1.5,” or “LADA” (Latent Autoimmune Diabetes in Adults), recent research suggests that the distinction between type 1 and type 2 diabetes is less clear-cut than previously thought. In some cases, features of both types can coexist.…
-
Blood Sugar Trends: Defining What’s Truly “Normal”
With the rise of direct-to-consumer continuous glucose monitoring, there has been growing interest in understanding blood sugar trends. Reasons for CGM use include to improve metabolic health, prevent diabetes, enhance sports performance and recovery, or simply out of curiosity. Users can access real-time data, averages, trends, and insights at any time, day or night. With all this data, you might find yourself wondering: What do my numbers mean? Should I be concerned? Is this normal? All valid questions. Let’s explore the evidence behind defining “normal” blood sugar trends. Diagnosing Diabetes To define what is considered normal, it’s best to start…
